Background-Clopidogrel requires metabolic activation by cytochrome P450 2C19 (CYP2C19
I n recent years, clopidogrel has become established as a key antiplatelet therapy in patients with acute coronary syndromes or undergoing percutaneous coronary intervention (PCI). Proton pump inhibitors (PPIs) are often administered in combination with clopidogrel to help reduce the risk of gastrointestinal bleeding, a practice that is supported by current treatment guidelines. 1 Clopidogrel requires metabolic activation by cytochrome P450 enzymes, including cytochrome P450 2C19 (CYP2C19). 2, 3 Because many PPIs are metabolized by or are inhibitors of CYP2C19, there is a potential for drug-drug interactions that may affect the antiplatelet response and clinical efficacy of clopidogrel. 4 In addition, PPIs may affect drug absorption by altering gastric pH. 5 
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Recent pharmacokinetic and pharmacodynamic studies have investigated the effect of concomitant PPI therapy on the antiplatelet response elicited by clopidogrel. 6 -12 Overall, these studies showed that the coadministration of omeprazole, one of the most potent inhibitors of CYP2C19, was associated with reduced platelet inhibition compared with clopidogrel alone 6, 7, 10 and that PPI use overall was associated with increased platelet aggregation and was an independent predictor of high residual platelet reactivity in patients receiving clopidogrel. 8, 9 However, studies also suggest that less potent inhibitors of CYP2C19 such as pantoprazole do not affect the platelet response to clopidogrel. 11, 12 Although a reduction in platelet inhibition would be expected to manifest as a reduction in the clinical efficacy of clopidogrel therapy, recent clinical outcome studies have reported conflicting results. Several small studies [13] [14] [15] and retrospective analyses of 3 larger population-based studies 16 -18 have reported an increased risk of cardiovascular events for patients receiving combined PPI and clopidogrel compared with clopidogrel alone. In contrast, results and retrospective analyses of 3 large randomized clinical trials of Ͼ41 000 clopidogrel-treated patients ( 8, 19, 20 In light of these conflicting results from controlled clinical trials, further large-scale investigation into the real-world efficacy of PPI and clopidogrel combination therapy is required.
The French Registry of Acute-ST-Elevation and Non-STElevation Myocardial Infarction (FAST-MI) gathered comprehensive data on the management and outcomes of patients admitted to intensive care units with definite MIs. 21 The present analysis compared treatment outcomes in patients who did or did not receive clopidogrel and/or PPIs to assess the clinical impact of PPI treatment on the efficacy of clopidogrel therapy, with specific focus on CYP2C19 genetic polymorphisms.
Methods

Population
The FAST-MI methods and population have been described in detail in previous publications. 21, 22 In summary, all patients Ͼ18 years of age were eligible for inclusion if they were admitted to an intensive care unit with a definite MI within 48 hours of symptom onset. The diagnosis of definite MI required elevated troponin, creatine kinase or creatine kinase-MB levels more than twice the upper limit of normal, and at least one of the following: symptoms compatible with acute MI, the appearance of pathological Q waves on ECG (Ͼ0.04 seconds), or persisting ST elevation/depression Ͼ0.1 mV. Patients were excluded from the registry if they were diagnosed with an iatrogenic MI, if the diagnosis of definite MI was invalidated in favor of an alternative, or if they had unstable angina with no elevation of cardiac necrosis biomarkers. All patients provided informed consent for participation in the registry, and the protocol was reviewed by the Committee for the Protection of Human Subjects in Biomedical Research of St Antoine University Hospital. Treatment was carried out according to the participating physicians' discretion independently of the study.
Data Collection
Data were collected from computerized report forms for individual patients. Baseline demographics and clinical characteristics were recorded on admission, and treatment management, clinical events, and survival were assessed during the following 48 hours, throughout the remainder of the hospital stay, and at discharge. To limit bias potentially related to the occurrence of the index episode when the patients were on either of the medications studied, all analyses were performed on the clopidogrel-and PPI-naïve population (ie, patients not on clopidogrel or on a PPI at the time of the index episode). The results were similar, however, when the analyses were performed in the whole population (see the online-only Data Supplement).
Statistical Analyses
All continuous variables are described as meanϮSD and categorical variables as absolute frequencies and percentages. Comparisons between groups were made with the use of t tests for quantitative variables.
In-hospital events were analyzed with logistic regression analyses according to the use of PPI at 48 hours. Cumulative 1-year events were analyzed with Cox multivariate analyses comparing patients on continued PPI therapy, defined as patients receiving PPI treatment at 48 hours and at discharge, versus patients receiving no PPI treatment, defined as patients with no PPI at 48 hours or at discharge (censoring patients who started or stopped PPI use at discharge). Patients who died during the index hospitalization were categorized into the continued PPI group if PPIs had been prescribed within 48 hours of admission or into the non-PPI group if they had not received PPI within 48 hours. A sensitivity analysis was performed in the same population limited to hospital survivors; for this specific analysis, discharge medications (aspirin, ␤-blockers, angiotensin-converting enzyme [ACE] inhibitors, and statins) were added to the multivariate model. All variables listed in Table 1 were used as covariates in the logistic and Cox models.
Propensity analyses were also performed to compare patient subgroups with a similar likelihood to receive PPI treatment. 23 A propensity score for receiving PPI treatment at 48 hours was calculated with logistic regression analysis. All variables listed in Table 1 were used to generate the propensity score. Patients with or without PPI therapy were then matched on the propensity score, and all in-hospital outcomes were measured in these propensity-matched cohorts. Likewise, a second propensity score for getting PPI treatment at hospital discharge (in patients on clopidogrel at discharge) was calculated using the same variables with the addition of in-hospital procedures (reperfusion therapy, PCI) and discharge medications, and the 2 cohorts matched on this propensity score were compared for 1-year outcomes. Kaplan-Meier curves were generated for 1-year event-free survival for propensity-matched cohorts.
Further analyses were performed to assess the impact of type of PPI treatment and CYP2C19 genetic polymorphisms. For comparison of outcomes according to genotype and because the homozygote groups were small, adjustment variables were limited to sex, Global Registry of Acute Coronary Events (GRACE) score, and risk factors (hypertension, diabetes mellitus, current smoking, and hyperlipidemia). For all tests, values of PϽ0.05 were considered statistically significant.
Results
Patient Population and Baseline Characteristics
The FAST-MI registry included a total of 3670 patients in 223 centers throughout France, of whom 2744 were clopidogrel-and PPI-naïve at the time of the index episode. Among them, 2353 received clopidogrel within 48 hours. Their baseline characteristics by clopidogrel and PPI use are summarized in Table 1 . Some consistent significant differences between the no PPI and PPI groups were observed in the baseline characteristics (eg, diabetes mellitus, history of MI or coronary artery bypass graft (CABG), previous PPI or aspirin, and medications or procedures after admission), whether the patients received clopidogrel or not. The findings were similar in the whole population (see the online-only Data Supplement). However, after matching of the population based on propensity score, there were no significant differences between the no PPI and PPI cohorts ( Table 2 ).
In-Hospital Events and 1-Year Outcomes
In-hospital and 1-year outcomes are summarized in Table 3 . The use of PPI was not associated with the risk of any of in-hospital ischemic events. In clopidogrel-treated patients, the adjusted odds ratio (OR) for death, reinfarction, or stroke was 0.90 (95% confidence interval [[CI], 60 to 1.35) in PPI users versus those without PPI. Likewise, continued PPI treatment was not an independent predictor of the overall 1-year survival in patients treated with clopidogrel (hazard ratio [HR], 0.97; 95% CI, 0.87 to 1.08) or 1-year MI, stroke, or death (HR, 0.98; 95% CI, 0.90 to 1.08). No significant increased risk was observed for PPI use when the analyses were restricted to hospital survivors (HR, 0.97; 95% CI, 0.67 to 1.41; Pϭ0.89; HR, 1.06; 95% CI, 0.78 to 1.43; Pϭ0.70 for death and 1-year MI, stroke, or death, respectively). Similarly, no difference was observed in the overall population according to the use of PPI for any in-hospital or 1-year events (see the online-only Data Supplement). (18) 33 (21) Peripheral artery disease, n (%) 63 (7) 72 (5)* 25 (11) 18 (12) Family history, n (%) 231 (26) 386 (27) 24 (10) 26 (17) History of, n (%) MI 125 (14) 141 (10) ‡ 40 (17) 22 (14) PCI 93 (10) 96 (7) ‡ 19 (8) 11 (7) CABG 40 (4) 37 (3)* 16 (7) 9 (6) Heart failure 32 (4) 36 (3) 21 (9) 20 (13) Stroke 35 (4) 41 (3) 18 (8) 15 (10) Prior treatment with, n (%) used and compares them with outcomes in those without PPI. There was no difference in incidence for any in-hospital outcome, although the analyses were limited by the relatively small absolute numbers of events in some instances. Among hospital survivors using continued PPI, the 1-year events did not differ for any PPI. However, a numerically higher percentage of events was observed with pantoprazole compared with other PPIs (Table 4) .
Individual PPI Use
Propensity-Matched Cohort Analysis
In-hospital events were similar in the more robust propensitymatched cohort analysis (Figure 1) . Similarly, in hospital survivors discharged on clopidogrel, no significant difference was observed for 1-year stroke, MI, or death between PPI and no PPI use (Kaplan-Meier analysis, 9% and 8%; HR, 1.24; 95% CI, 0.87 to 1.78; Pϭ0.24; Figure 2) . One-year mortality also showed no significant differences for PPI compared with no PPI use (HR, 1.15; 95% CI, 0.73 to 1.83; Pϭ0.54).
Bleeding and Transfusion
No significant differences were observed for the incidence of in-hospital major bleeding and/or transfusion in the PPI-and clopidogrel-naïve population ( 
CYP2C19 Genotype
Of the 2353 clopidogrel-and PPI-naïve patients at admission who received clopidogrel within 48 hours, 1579 patients (67%) contributed a sample to the DNA bank. For in-hospital events, the percentages of events for patients with versus without early PPI treatment were 3.6% versus 5.4%, 3.5% versus 4.9%, and 12.0% versus 5.3% in patients with 0, 1, or 2 CYP2C19 variant alleles, respectively (adjusted OR in patients receiving PPI: 0.68 [95% CI, 0.37 to 1.25], 0.34 [95% CI, 0.11 to 1.08], and 1.05 [95% CI, 0.03 to 34.6], respectively). In patients discharged on clopidogrel, the occurrence of 1-year death, MI, or stroke also did not differ significantly by PPI use, whatever the genotype (Table 5 ). In patients without loss-of-function alleles, 1-year event rates were 9.2% versus 8.5% (adjusted HR, 1.13; 95% CI, 0.74 to 1.74) in those discharged on PPI versus those not on PPI; in patients with 1 loss-of-function allele, 1-year event rates were 5.8% versus 6.4% (adjusted HR, 1.02; 95% CI, 0.44 to 2.40); and in patients with 2 loss-of-function alleles, 1-year event rates were 6.7% versus 15.8% (adjusted HR, 0.25; 95% CI, 0.02 to 3.58).
In the propensity-matched cohorts for in-hospital events, 1015 patients (67%) provided a DNA sample. In-hospital death, recurrent MI, or stroke was observed in 4.0% and 5.6% of CYP2C19 wild-type patients treated with PPI and those not treated with PPI, respectively (OR, 0.70; 95% CI, 0.35 to 1.40; Pϭ0. 31) Overall, there was no significant interaction between genotype and impact of PPI on the incidence of in-hospital and 1-year ischemic events (Pϭ0.57 and Pϭ0.64 for in-hospital events and for hospital survivors, respectively).
Discussion
In the large FAST-MI registry of patients admitted to intensive care units in France with definite MI, the use of a PPI 
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was not associated with a significantly increased risk of in-hospital mortality, 1-year mortality, or in-hospital bleeding in patients receiving clopidogrel and did not significantly affect 1-year MI-and stroke-free survival. No trend for increased hazards in patients receiving PPI was observed, and the numbers of events were actually lower in most instances. These findings remained unchanged after adjustment for measured confounders and in the propensity-matched cohorts for PPI use. We found no significant association between genotype for CYP2C19 and PPI use on clinical outcomes, although a numerically higher rate of in-hospital ischemic events was observed in PPI-treated patients in the presence of 2 reduced function alleles. In addition to the lack of a clear association between PPI use and rates of major adverse cardiac events, PPI use did not appear to affect rates of major bleeding or transfusion. If the relationship was clinically meaningful, it would have been expected that bleeding would be increased in patients not on PPIs.
The study reported here represents new information, not only because it uses real-life data from clinical practice but also because individual PPI treatments and the presence of CYP2C19 polymorphisms were taken into consideration and propensity-matching was performed to compensate for confounding factors and baseline differences compared with those requiring clopidogrel treatment alone. These findings are also consistent with previous analyses. 8, 19, 24, 25 In a retrospective analysis of the TRITON-TIMI 38 study, a randomized controlled trial comparing prasugrel and clopidogrel in Ͼ13 000 patients with acute coronary syndrome, no association was observed between PPI use and the primary end point (risk of MI, cardiovascular death, or stroke) for patients treated with clopidogrel. 8 There also appeared to be no clinically relevant effect of PPI use on clopidogrel efficacy reported in PLATO, a randomized controlled trial comparing clopidogrel and ticagrelor in 18 624 patients with acute coronary syndromes, 19 or a pooled analysis of 18 565 patients treated with clopidogrel after PCI or acute coronary syndrome. 25 Although these are all posthoc analyses, they are based on patient populations from large randomized clinical trials in which medications used during the entire follow-up were carefully monitored. Recently, a randomized clinical trial (Clopidogrel and the Optimization of Gastrointestinal Events [COGENT-1]) has been completed comparing clopidogrel, omeprazole, and aspirin therapy with clopidogrel and aspirin alone in patients recently experiencing ST-elevation MI, non-ST-elevation MI, or coronary artery stent placement. 26 Similar rates of a composite of cardiovascular death, nonfatal MI, CABG, PCI, or confirmed ischemic stroke were observed in all groups, with a 45% reduction in gastrointestinal bleeding reported for clopidogrel/omeprazole/aspirin combination therapy. 26 In contrast, some previous retrospective analyses have shown an increase in cardiovascular events with coadministration of PPIs and clopidogrel. [15] [16] [17] These retrospective studies differ from the pivotal clinical trial analyses detailed above (TRITON-TIMI 38 and PLATO), with greater population heterogeneity, less control of assessments, and no consideration of the effects of CYP2C19 polymorphisms. The Juurlink et al 16 study was a nested, case-control study in Ontario residents Ն66 years of age. Multivariate analysis showed an increased risk with concomitant PPIs of repeat admission for MI Ͻ90 days after discharge for first acute MI. 16 Ho et al 17 reported a retrospective analysis of 8205 acute coronary syndrome patients in whom the incidence of the primary outcome (death or rehospitalization for acute coronary syndrome) was higher in patients receiving concomitant PPIs. 17 The use of medications was based on pharmacy refill records, but sensitivity analyses showed consistent results. Gupta et al 15 reported a retrospective analysis of a study involving 315 patients from a single center in the United States who had undergone PCI. Multivariate analyses showed a significant increase in the risk of the primary outcome (cardiovascular death, MI, or target-vessel failure) with concomitant PPI (outcome rate, 38% [no PPI] versus 56% [PPI]; adjusted OR, 1.95; 95% CI, 1.09 to 3.49; Pϭ0.025).
It must be considered that the absence of a clinical impact of concomitant PPI and clopidogrel use is counterintuitive to previous observations that PPIs attenuate the antiplatelet effects of clopidogrel. 6, 7, 10 However, these contrasting findings are not without precedent. Atorvastatin has been reported to attenuate the antiplatelet effect of clopidogrel in a dosedependent manner 27 but is not associated with an increase in ischemic events. 28, 29 It is possible that the reduction in Figure 1 . In-hospital death and in-hospital ischemic events (death, MI, or stroke) in patients matched on the propensity score of receiving PPI or no PPI treatment at 48 hours. Major bleed, n (%) 16 (2) 17 (2) 5 (2) 1 (2) Death, MI, or stroke, n % ‡ 60 (10) 43 (7) 20 (8) 1 (3) 12 (15) Adjusted HR (95% CI) antiplatelet activity is insufficient to manifest as a change in clinical outcome or that additional factors may confound the outcomes. In addition, the interaction of PPIs on the antiplatelet effect of clopidogrel varies according to the measure used, 7 and there is lingering uncertainty about the link between platelet function tests and clinical outcomes. 30 This emphasizes that surrogate end points should not be used to predict clinical outcomes, particularly in patient populations with multiple comorbidities. We found strong evidence to suggest that the use of concomitant clopidogrel and PPI treatment in patients without CYP2C19 loss of function does not carry with it an increased risk of cardiovascular events or mortality. This is a key finding, considering the widespread use of clopidogrel and PPI in acute coronary syndrome patients. Similarly, no significant change in the risk of cardiovascular events or mortality was observed for patients with CYP2C19 loss of function.
However, patients carrying 2 CYP2C19 loss-of-function alleles and treated with PPI had a numerically higher incidence of in-hospital major ischemic events than those with no PPI. Therefore, because of the low number of patients and resultant large CI ranges, the possibility that a higher early risk may exist in patients with 2 CYP2C19 variant alleles cannot be dismissed. Further large-scale studies incorporating CYP2C19 genotyping to evaluate the influence of PPI use on the clinical response to clopidogrel would be useful to effectively guide therapeutic decisions.
Limitations
The FAST-MI registry was a nonrandomized observational study. Although nonrandomized observational studies provide important information on real-world clinical practice and involve a more realistic heterogeneous patient population, they have inherent limitations in their design. Despite consecutive patients being included in the FAST-MI registry and data being audited, potential confounding factors may go unrecorded, and clinical information may be missing or incomplete. In this study, the individual subgroups may have been underpowered to detect a difference between different PPI treatments, particularly relative to the impact of each individual PPI, which may explain the numerically higher number of events in the pantoprazole group, a less potent inhibitor of CYP2C19 than omeprazole. 31 Moreover, PI use was not followed up after hospital discharge. Patients could switch categories, which runs the risk of biasing the results toward the null among hospital survivors. In addition, DNA testing was performed on only a proportion of the study population. The study centers were limited to France, and the national coverage was only 60% of intensive care units, although it has also been shown that the study centers represented the broad spectrum of hospitals that treat patients with acute MI. 23 The use of sensitivity analyses and propensity matching may compensate for confounding factors and potential bias. Nevertheless, caution should be taken when interpreting the results.
Conclusions
Overall, our findings provide a strong suggestion for the lack of a clinically relevant interaction between PPI and clopidogrel. PPI use was not associated with an increased risk of cardiovascular events or mortality in patients treated with clopidogrel for recent MI. Therefore, at the current stage, our results do not support the avoidance of PPI use in patients receiving clopidogrel who are at increased risk of gastrointestinal bleeding, particularly patients without CYP2C19 loss of function. Further randomized studies are needed, however, to confirm these results.
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